A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs

Journal of Medicinal Chemistry

Volumn 47, Issue 23, 2004, Pages 5683-5689

  Parker, Laurie L ^a   Lacy, Stephen M ^a   Farrugia, Louis J ^a   Evans, Cameron ^a   Robins, David J ^a   O'Hare, C Caroline ^b   Hartley, John A ^b   Jaffar, Mohammed ^c   Stratford, Ian J ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE; 1,4,7,10 TETRAAZACYCLODODECANE; CHLORMETHINE; COPPER COMPLEX; CYCLAM; CYTOTOXIN; MACROCYCLIC COMPOUND; METAL COMPLEX; MUSTARD GAS DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CELL HYPOXIA; CELL LINE; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LUNG TUMOR; OXIDATION REDUCTION REACTION; STRUCTURE ACTIVITY RELATION;

EID: 7444241438     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049866w     Document Type: Article

References (51)

1. Wouters, B. G.; Weppler, S. A.; Koritzinsky, M.; Landuyt, W.; Nuyts, S.; et al. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 2002, 38, 240-257.
2. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41, 31-39.
3. Brizel, D. M.; Light, K.; Zhou, S. M.; Marks, L. B. Conformal radiation therapy treatment planning reduces the dose to the optic structures for patients with tumors of the paranasal sinuses. Radiother. Oncol. 1999, 51, 215-218.
4. Teicher, B. A. Hypoxia and Drug-Resistance. Cancer Metastasis Rev. 1994, 13, 139-168.
5. Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56, 4509-4515.
6. Graeber, T. G.; Osmanian, C.; Jacks, T.; Housman, D. E.; Koch, C. J.; et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379, 88-91.
7. Cullis, P. M.; Green, R. E.; Malone, M. E. Mechanism and reactivity of chlorambucil and chlorambucil-spermidine conjugate. J. Chem. Soc., Perkin Trans. 2 1995, 1503-1511.
8. Grando, S. A. Mucocutaneous cholinergic system is targeted in mustard-induced vesication. Life Sci. 2003, 72, 2135-2144.
9. Mattes, W. B.; Hartley, J. A.; Kohn, K. W. DNA-sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res. 1986, 14, 2971-2987.
10. Rink, S. M.; Hopkins, P. B. Direct evidence for DNA intrastrand cross-linking by the nitrogen-mustard mechlorethamine in synthetic oligonucleotides. Bioorg. Med. Chem. Lett. 1995, 5, 2845-2850.
11. Hartley, J. A.; Berardini, M. D.; Souhami, R. L. An agarose-gel method for the determination of DNA interstrand cross-linking applicable to the measurement of the rate of total and 2nd-arm cross-link reactions. Anal. Biochem. 1991, 193, 131-134.
12. Henderson, N. D.; Plumb, J. A.; Robins, D. J.; Workman, P. Synthesis and anti-cancer activity of 2,6-disubstituted W-methylpiperidine derivatives and their W-oxides. Anti-Cancer Drug Des. 1996, 11, 421-438.
13. Henderson, N. D.; Lacy, S. M.; O'Hare, C. C.; Hartley, J. A.; McClean, S.; Wakelin, L. P. G.; Kelland, L. R.; Robins, D. J. Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA. Anti-Cancer Drug Des. 1998, 13, 749-768.
14. Anderson, F. M.; O'Hare, C. C.; Hartley, J. A.; Robins, D. J. Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agents. Anti-Cancer Drug Des. 2000, 15, 119-126.
15. Wilson, W. R.; Moselen, J. W.; Cliffe, S.; Denny, W. A.; Ware, D. C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins-the cobalt(III)-nitrogen mustard complex SN-24771. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 323-327.
16. Ware, D. C.; Palmer, B. D.; Wilson, W. R.; Denny, W. A. Hypoxiaselective antitumor agents 0.7. Metal-complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins - synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem. 1993, 36, 1839-1846.
17. Blower, P. J.; Dilworth, J. R.; Maurer, R. I.; Mullen, G. D.; Reynolds, C. A.; et al. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J. Inorg. Biochem. 2001, 85, 15-22.
18. Stratford, I. J.; Stephens, M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16, 973-976.
19. Deck, K. M.; Tseng, T. A.; Burstyn, J. N. Triisopropyltriazacyclononane copper(II): An efficient phosphodiester hydrolysis catalyst and DNA cleavage agent. Inorg. Chem. 2002, 41, 669-677.
20. Li, S. A.; Yang, D. X.; Li, D. F.; Huang, J.; Tang, W. X. Carboxyester hydrolysis promoted by di-zinc(II) macrocyclic polyamine complexes with hydroxyethyl pendants: a model study for the role of the serine alkoxide nucleophile in zinc enzymes. New J. Chem. 2002, 26, 1831-1837.
21. Martell, A. E.; Motekaitis, R. J. The Determination and Use of Stability Constants; VCH: New York, 1988.
22. Osborne, M. R.; Wilman, D. E. V.; Lawley, P. D. Alkylation of DNA by the nitrogen-mustard bis(2-chloroethyl)methylamine. Chem. Res. Toxicol. 1995, 8, 316-320.
23. Hancock, R. D.; Wade, P. W.; Ngwenya, M. P.; Desousa, A. S.; Damu, K. V. Ligand design for complexation in aqueous solution 0.2. Chelate ring size as a basis for control of size-based selectivity for metal ions. Inorg. Chem. 1990, 29, 1968-1974.
24. Turonek, M. L.; Duckworth, P. A.; Laurence, G. S.; Lincoln, S. F.; Wainwright, K. P. Equilibrium and kinetic studies of complexes of the pendant donor macrocycles N,N′,N″,N‴-tetrakis(2-hydroxyethyl)-l,4,7, 10-tetraazacyclododecane(Thec-12) and N,N′,N″,N‴-tetrakis(2- hydroxyethyl)-1,4,8,12-tetraazacyclopentadecane (Thec-15). Inorg. Chim. Acta 1995, 230, 51-57.
25. de Abreu, F. C.; Ferraz, P. A. D.; Goulart, M. O. F. Some applications of electrochemistry in biomedical chemistry. Emphasis on the correlation of electrochemical and bioactive properties. J. Braz. Chem. Soc. 2002, 13, 19-35.
26. Ross, D.; Beall, H. D.; Siegel, D.; Traver, R. D.; Gustafson, D. L. Enzymology of bioreductive drug activation. Br. J. Cancer 1996, 74, S1-S8.
27. Moi, M. K.; Meares, C. F.; McCall, M. J.; Cole, W. C.; Denardo, S. J. Copper chelates as probes of biological systems-stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem. 1985, 148, 249-253.
28. Jones-Wilson, T. M.; Deal, K. A.; Anderson, C. J.; McCarthy, D. W.; Kovacs, Z. et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nuclear Med. Biol. 1998, 25, 523-530.
29. Motekaitis, R. J.; Rogers, B. E.; Reichert, D. E.; Martell, A. E.; Welch, M. J. Stability and structure of activated macrocycles. Ligands with biological applications. Inorg. Chem. 1996, 35, 3821-3827.
30. Martell, A. E.; Smith, R. M. Critical stability constants; Plenum Press: New York; London, 1974-present.
31. Maurer, R. I.; Blower, P. J.; Dilworth, J. R.; Reynolds, C. A.; Zheng, Y. F.; et al. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J. Med. Chem. 2002, 45, 1420-1431.
32. Boswell, C. A.; Sun, X.; Wang, M.; Ramos, B.; Weisman, G. R.; et al. Relationship between reduction potential and in vivo stability of copper-azamacrocycle complexes. J. Labelled Compd Radiopharm. 2001, 44 (Suppl. 1), S770-S772.
33. Madeyski, C. M.; Michael, J. P.; Hancock, R. D. N,N′,N″, N‴-Tetrakis(2-hydroxyethyl)cyclam, an N-donor macrocycle with rapid metalation reactions. Inorganic Chemistry 1984, 23, 1487-1489.
34. Buoen, S.; Dale, J.; Groth, P.; Krane, J. 1,4,7,10-Tetrakis(2- hydroxyethyl)-1,4,7,10-tetraazacyclododecane - a strong cation complexes J. Chem. Soc., Chem. Commun. 1982, 1172-1174.
35. Huskens, J.; Sherry, A. D. Coordination chemistry and molecular mechanics study of the magnesium(II) and calcium(II) complexes of trisubstituted 1,4,7-triazacyclononane derivatives. J. Chem. Soc., Dalton Trans. 1998, 177-184.
36. Malachowski, M. R.; Tomlinson, L. J.; Parker, M. J.; Davis, J. D. The design and synthesis of novel dinucleating macrocycles derived from cyclam. Tetrahedron Lett. 1992, 35, 1395-1398.
37. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography; 1997; part A, pp 307-326.
38. Blessing, R. H. DENZOX - Program for processing Denzo x files; Modified for KappaCCD data, Farrugia, L. J., Muir, K. W., Eds.; 2001.
39. Coppens, P.; Leiserowitz, L.; Rabinovich, D. Calculation of absorption corrections for camera and diffractometer data. Acta Crystallogr. 1965, 18, 1035-1038.
40. Blessing, R. H. Outlier treatment in data merging. J. Appl. Crystallogr. 1997, 30, 421-426.
41. Blessing, R. H. An empirical correction for absorption anisotropy. Acta Crystallogr. 1995, A51, 33-38.
42. Beurskens, P. T.; Beurskens, G.; de Gelder, R.; Garcia-Granda, S.; Gould, R. O.; et al. DIRDIF-99 program system; Crystallography Laboratory: University of Nijmegen, The Netherlands.
43. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. Completion and refinement of crystal structures with SIR92. J. Appl Crystallogr. 1993, 26, 343-350.
44. Sheldrick, G. M. SHELXL-97 a program for crystal structure refinement; University of Gttingen: Germany, Release 97-2.
45. International Tables for Crystallography, Volume C Mathematical, Physical and Chemical Tables; Kluwer: Dordrecht, 1995; Tables 4.2.4.2; 4.2.6.8; 6.1.1.4.
46. Spek, A. L. PLATON, An integrated tool for the analysis of the results of a single-crystal structure determination. Acta Crystallogr. 1990, A46, C34.
47. Farrugia, L. J. ORTEP-3 for Windows - a version of ORTEP - III with a Graphical User Interface (GUI). J. Appl. Crystallogr. 1997, 30, 565.
48. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837-838.
49. Osella, D.; Ferrali, M.; Zanello, P.; Laschi, F.; Fontani, M. et al. On the mechanism of the antitumor activity of ferrocenium derivatives. Inorg. Chim. Acta 2000, 306, 42-48.
50. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assay. J. Immunol. Methods 1983, 65, 55.
51. Lee, M.; Rhodes, A. L.; Wyatt, M. D.; Forrow, S.; Hartley, J. A. Design, synthesis, and biological evaluation of DNA-sequence and minor groove selective alkylating agents. Anti-Cancer Drug Design 1993, 8, 173-192.